Visualitzant per matèria 

Visualitzant per matèria "Palbociclib"

Ara mostrant els elements 1-3 de 3

    • CDK6 is activated by the atypical cyclin I to promote E2F-mediated gene expression and cancer cell proliferation 

      Quandt Herrera, Eva; Masip Sales, Núria; Hernández Ortega, Sara; Sánchez-Botet, Abril; Gasa, Laura; Fernández-Elorduy, Ainhoa; Plutta, Sara; Martínez Láinez, Joan Marc; Bru Rullo, Samuel; Munoz-Torres, Pau M.; Floor, Martin; Villà-Freixa, Jordi; MORRIS, May C.; Vidal, August; Villanueva, Alberto; Clotet, Josep; Ribeiro, Mariana P. C. (Molecular Oncology, 2023)
      Cyclin-dependent kinases (CDKs), together with their cyclin partners, are the master cell cycle regulators. Remarkably, the cyclin family was extended to include atypical cyclins, characterized by ...

    • Estudi de la ciclina atípica CCNI com a potencial activador de CDK6 en línies de càncer de mama 

      Masip Sales, Núria (Data de defensa: 2022-02-09)
      Fa quasi 40 anys del descobriment de les ciclines, les proteïnes oscil·lants tradicionalment dividies en dos grups, “cicle cel·lular” i “ciclines transcripcionals”, que duen a terme els seus rols juntament ...

    • Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial 

      Pascual, T.; Villacampa Javierre, Guillermo; Oliveira, Mafalda; Escrivá-de-Romaní, S.; Pernas, S.; Paré, L.; Adamo, Barbara; Cortés, J.; Perelló, A.; Galán, M.; Melé, Mireia; Villanueva, L.; González-Rodríguez, Marta; Tolosa, Pablo; Gonzalez-Farre, Blanca; Galván, Patricia; Canes, Jordi; Nuciforo, Paolo; Ferrero-Cafiero, Juan Manuel; Gonzàlez Farré, Xavier; Villagrasa-Gonzalez, Patricia; Prat, Aleix; Ciruelos, Eva (ESMO Open, 2025-09-01)
      Background: The SOLTI-1303-PATRICIA trial (NCT02448420) is a phase II study investigating palbociclib and trastuzumab, with or without endocrine therapy, in hormone receptor (HR)-positive/human epidermal ...